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Effects of Pranlukast Hydrate on
Airway Hyperresponsiveness in
Non-Asthmatic Patients with Japanese
Cedar Pollinosis
Hironori Sagara1, Tatsuo Yukawa1,2, Ryuichi Kashima1, Takenori Okada1 and Takeshi Fukuda1
ABSTRACT
Background: Recent studies have suggested that allergic rhinitis is closely related to bronchial asthma, re-
flecting the “one airway-one disease” hypothesis. It is unclear if the effects of pranlukast, a leukotriene-receptor
antagonist, are consistent with this hypothesis.
Objective: The goal of the study was to determine if pranlukast has effects on the upper and lower airways
through a comparison of the effects of fexofenadine and pranlukast on airway hyperresponsiveness in non-
asthmatic patients with cedar pollinosis before the Japanese cedar pollen season and during the peak pollen
season.
Methods: Patients received fexofenadine hydrochloride plus oral mequitazine (fexofenadine group) or pranlu-
kast hydrate plus oral mequitazine (pranlukast group) as an initial treatment. Subsequent changes in airway re-
sponsiveness to acetylcholine were measured.
Results: Among patients in whom coughing developed during the peak pollen season, airway responsiveness
significantly increased in the fexofenadine group. In the pranlukast group, airway responsiveness did not in-
crease significantly, regardless of the presence or absence of coughing.
Conclusions: The results indicate that pranlukast hydrate inhibits airway hyperresponsiveness in non-
asthmatic patients with Japanese cedar pollinosis. In turn, this suggests that cysteinyl leukotrienes have a role
in increased airway responsiveness.
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INTRODUCTION
The concept of “one airway-one disease” proposed by
Grossman suggests that allergic rhinitis and bron-
chial asthma are closely related allergic diseases that
involve the entire airway, rather than separate dis-
eases of the upper or lower respiratory tract.1 Interna-
tional guidelines for the treatment of allergic rhinitis
have been proposed in the World Health Organiza-
tion Initiative on Allergic Rhinitis and its Impact on
Asthma (ARIA).2 These guidelines also emphasize in-
volvement of the upper and lower airways in allergic
rhinitis, again suggesting an interaction between al-
lergic rhinitis and bronchial asthma.
The upper airway has an influence on the lower air-
way, since the severity of rhinitis correlates positively
with clinical symptoms of asthma and increased se-
verity of rhinitis is associated with asthma exacerba-
tion.3 In non-asthmatic patients with allergic rhinitis,
bronchial mucosa eosinophil counts are often higher
than in healthy subjects, although not as high as
those for asthmatic patients.4 Airway responsiveness
in non-asthmatic patients with allergic rhinitis also
falls between those for asthmatic patients and healthy
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Table 1 Subject characteristics
P valuePranlukast group
Fexofenadine
group
N.S1)2.735.5±2.535.9±Age (year) 
N.S2)6/105/13Sex (M/F) 
N.S1)1.8163.3±1.6159.7±Height (cm) 
N.S2)12/412/6Atopy family 
history (＋/－) 
N.S1)1.110.9±1.712.8±Onset (years) 
N.S1)51.8200.7±39.9188.5±Total IgE 
(IU/ml) 
N.S3)0.34.2±0.23.7±Specific IgE 
(CAP score) 
cedar
N.S1)1179.917900±880.019120±PC20Ach 
(mg/ml) 
N.S1)65.9294.2±36.9241.7±Peripheral 
blood eosino-
phils (cel/ml)
Data are shown as means±S.E.; N.S.: Not significant; 1) Stu-
dent’ st test, 2) χ2 test, 3) Mann-Whitney U test; groups: fexofe-
nadine＋mequitazine, pranlukast＋mequitazine.
subjects, but is considered to be increased.5
Therapeutic agents for allergic rhinitis include na-
sal steroid sprays, chemical mediator release inhibi-
tors, antihistamines, leukotriene-receptor antagonists
(LTRAs), antiprostaglandin D2, and antithromboxane
A2. Cysteinyl leukotrienes are inflammatory media-
tors that have a common causative role in the patho-
genesis of allergic diseases in both the upper and
lower airways,6 and LTRAs are effective for both
bronchial asthma and allergic rhinitis.7-10 Thus,
LTRAs appear to inhibit allergic inflammation in both
airways. To examine this hypothesis, we compared
the effects on airway responsiveness of an LTRA with
those of a second-generation antihistamine during
the peak cedar pollen season in non-asthmatic pa-
tients with Japanese cedar pollinosis.
METHODS
SUBJECTS
The study included 34 non-asthmatic patients with a
diagnosis of Japanese cedar pollinosis according to
diagnostic guidelines for nasal allergy (2002).11 The
patients visited our clinic before the cedar pollen sea-
son from January 24 to February 19 in 2005 and re-
ceived a thorough explanation of the study protocol.
All subjects gave informed consent, and they were re-
examined after cedar pollen shedding (February 22)
especially during the peak pollen season from March
7 to April 9 in 2005.
DRUG ADMINISTRATION
Patients received fexofenadine hydrochloride (120
mgday, one 60-mg tablet twice daily) plus oral
mequitazine (6 mgday, one 3-mg tablet twice daily)
(fexofenadine group) or pranlukast hydrate (450 mg
day, two 112.5-mg capsules twice daily) plus oral
mequitazine (6 mgday, one 3-mg tablet twice daily)
(pranlukast group). The groups were established
based on the order of patient visits before the cedar
pollen season (January 24 to February 19). Use of na-
sal steroid sprays was avoided whenever possible,
and levocabastine hydrochloride eye drops and nasal
drops were permitted only on exacerbation of symp-
toms.
AIRWAY RESPONSIVENESS TO ACETYLCHO-
LINE
Acetylcholine was inhaled before the pollen season
(January 24 to February 19) and during the peak pol-
len season (March 7 to April 9) according to the stan-
dard method of Makino et al.12 Sensitivity to acetyl-
choline (PC20Ach) was defined as the concentration
of acetylcholine that provoked a 20% or more reduc-
tion in the forced expiratory volume in 1 second
(FEV1.0) after inhalation, compared with the baseline
value.
PULMONARY FUNCTION AND PERIPHERAL
BLOOD EOSINOPHIL COUNT
Pulmonary function tests were performed on a spi-
rometer (HI-801, CHEST M.I., Tokyo, Japan). FEV1.0
(AS-7, MINATO, Osaka, Japan) and peripheral blood
eosinophil counts were measured before the pollen
season and during the peak pollen season.
SYMPTOMS AND DAILY ACTIVITIES
Symptoms were assessed based on self-administered
questionnaires during the peak pollen season. Vari-
ables included nasal and ocular symptoms, the de-
gree of impairment of daily activities, and the fre-
quency and severity of coughing. Briefly, the fre-
quency of coughing was graded according to the
evaluation method proposed by Nishi et al.14: 0 indi-
cating none (never); 1 indicating infrequent (5 times
or less); 2 indicating somewhat frequent (6 to 10
times); 3 indicating frequent (11 to 20 times); and 4
indicating very frequent (21 times or more). The se-
verity of coughing was graded as follows: 0 indicating
none; 1 indicating mild, 2 indicating moderate; 3 indi-
cating severe; and 4 indicating very severe. Next, na-
sal and ocular symptoms, such as rhinorrhea, sneez-
ing, nasal congestion, nasal itching, itching of the
eyes, and watery eyes, were graded according to the
Japan Allergic Rhinitis Standard Quality-of-Life Ques-
tionnaire (JRQLQ No. 1)13: 0 indicating none; 1 indi-
cating mild; 2 indicating moderate; 3 indicating se-
vere; and 4 indicating very severe. The degree of im-
pairment of daily activities was graded according to
the 2002 diagnostic guidelines for nasal allergy: 1 in-
dicating unable to work or study; 2 indicating diffi-
culty in starting to work or study; 3 indicating inter-
mediate between 2 and 4; 4 indicating almost no prob-
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Table 2 Clinical characteristics of 18 cedar polinosis subjects treated with fexofenadine and mequitazine
Specific IgE (CAP score)Total IgE 
(IU/ml) 
Onset
(years) 
Atopy family 
history
Height
(cm) Sex
Age
(year) 
Subject
No. MiteHDArtemisiaAmbrosiaDacylisCypressCedar
230100310812 (＋) 170M48 1
3300034210 7 (＋) 167F26 2
0000034 63 3 (－) 153F34 3
1200024 4910 (－) 153F27 4
330032467720 (－) 153F34 5
2200013 5418 (＋) 162F43 6
430003525015 (＋) 158F31 7
0000004ND10 (＋) 153F23 8
3300023250 3 (＋) 169M38 9
000000321314 (－) 158F4610
000002419325 (＋) 166M5211
000000311926 (＋) 164M5912
213042420020 (－) 155F4513
330000423115 (＋) 158F2614
0002323ND10 (－) 172M3415
2200223164 3 (＋) 153F2816
0000003 4612 (＋) 155F2717
0002035ND 8 (＋) 155F2518
ND: Not detected.
Table 3 Clinical characteristics of 16 cedar polinosis subjects treated with pranlukast and mequitazine
Specific IgE (CAP score)Total IgE 
(IU/ml) 
Onset
(years) 
Atopy family 
history
Height 
(cm) Sex
Age 
(year) 
Subject 
No. MiteHDArtemisiaAmbrosiaDacylisCypressCedar
220003620015 (＋) 173M39 1
2202025740 9 (＋) 168M37 2
001002330012 (－) 164F60 3
0000236 6915 (＋) 156F26 4
0000023 6610 (＋) 173M45 5
666033615616 (＋) 159F36 6
0000023103 9 (－) 156F30 7
222233516620 (＋) 153F42 8
330003446910 (＋) 173M27 9
0000403 93 3 (－) 164M2310
4422235ND 8 (＋) 158F3411
0000034 51 5 (－) 157F2212
0000234 25 9 (＋) 163F3013
0000034 2213 (＋) 160F4014
4400003154 6 (＋) 161F2515
330000341015 (＋) 174M5216
ND: Not detected.
lems with working or studying; and 5 indicating no
problems.
STATISTICAL ANALYSIS
Data are expressed as means ± SD. Demographic
characteristics were compared between groups by
the chi-square test, Student t test, and Mann-Whitney
U test. Airway responsiveness, peripheral blood
eosinophil counts, and FEV1.0 were compared within
groups by paired t-test and between groups by the
Student t-test. Symptoms and daily activities were
compared within groups by the Mann-Whitney U
Sagara H et al.
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Fig. 1 Airway responsiveness to acetylcholine (Ach). Seasonal variation of PC20Ach val-
ues in non-asthmatic subjects with Japanese cedar polinosis. In the fexofenadine group, 
airway responsiveness to acetylcholine increased significantly during the peak polen sea-
son compared with before the polen season. However, airway responsiveness did not in-
crease significantly in the pranlukast group.
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Fig. 2 Respiratory function. Seasonal variation of FEV1.0 in non-asthmatic subjects with 
Japanese cedar polinosis. No significant diference in FEV1.0 was observed before and 
during the peak polen season.
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test. Multiple linear regression analysis was used to
compare the correlations among sensitivity to acetyl-
choline (PC20Ach) and symptom score. All P values
are two-tailed and P < 0.05 was considered to indicate
statistical significance.
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Fig. 3 Peripheral blood eosinophil. Seasonal comparison of eosinophil counts in periph
eral blood. Eosinophil counts increased significantly during the peak polen season com
pared with before the polen season in the Fexofenadine group. No significant diference in 
eosinophil counts was observed before and during the peak polen season in the Pranlu
kast group.
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Fig. 4 Score of nasal symptoms, ocular symptoms and daily life activity during 
the peak polen season. There was a significant diference in stufy nose and daily 
life in the Pranlukast group compared with the Fexofenadine group. Data are pre
sented as means±SD.
0.50 1 1.5 2 2.5 3 3.5
Symptom score
Runny nose
Sneezing
Stuffy nose
Itchy nose
Itchy eyes
Watery eyes
Usual 
daily activity
Score
0 0.5 1 1.5 2.52 3 3.5 4 4.5
0.04
Mann-Whitney’s U-test
Fexofenadine group (n ＝ 18)
Pranlukast group (n ＝ 16)
0.0004
RESULTS
DEMOGRAPHIC CHARACTERISTICS
The mean demographic characteristics of each group
are shown in Table 1, and the characteristics for indi-
vidual patients are shown in Table 2, 3. Of the 34 pa-
tients in the study, 18 received fexofenadine hydro-
chloride plus oral mequitazine (5 men and 13 women;
mean age, 35.9 ± 2.5 years [mean ± standard error])
and 16 received pranlukast hydrate plus oral mequi-
tazine (6 men and 10 women; mean age, 35.5 ± 2.7
years). All patients tested positive for Japanese cedar
pollen antigen, and many patients also tested positive
for hinoki (Chamaecyparis obtusa), house dust, and
Sagara H et al.
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Fig. 5 Frequency and severity of cough during the peak polen season. The frequency of cough
ing in subjects with cough in the pranlukast group was significantly lower than that of subjects with 
cough in the fexofenadine group.
N.S.
N.S.
P value＊
Total
Cough
（＋）
Cough
（－）
0 20 40 60 80 100 (%) 0 20 40 60 80 100 (%) 
0 20  40 60 80 100 (%) 0 20 40 60 80 100 (%)
None Not often Relatively often Often Quite often
＊Mann-Whitney’s U-test (vs Fexofenadine ＋ mequitazine)
None Mild Moderate Severe Very severe
N.S.
0.006
P value＊
Total
Cough
(＋)
Cough
(－)
Frequency of cough
Severity of cough
＊Mann-Whitney’s U-test (vs Fexofenadine ＋ mequitazine)
Fexofenadine group Pranlukast group
house-dust mite antigens. There were no significant
differences in age, sex ratio, height, family history of
atopic disease, duration of disease, serum IgE levels,
Japanese cedar-specific IgE (CAP score), airway hy-
perresponsiveness before the pollen season, and pe-
ripheral blood eosinophil counts between the groups.
AIRWAY RESPONSIVENESS
PC20Ach levels were compared before the pollen sea-
son and during the peak pollen season. In the fexofe-
nadine group the PC20Ach level decreased signifi-
cantly during the peak pollen season (p < 0.001), but
in the pranlukast group the PC20Ach level did not de-
crease significantly. PC20Ach levels during the peak
pollen season were significantly lower in the fexofe-
nadine group than in the pranlukast group (p < 0.001)
(Fig. 1).
PULMONARY FUNCTION
FEV1.0 before the pollen season did not differ signifi-
cantly from that during the peak pollen season in
either group (Fig. 2). The same results were indi-
cated in some to very frequent (6 times or over)
cough group (cough [+]), and none or infrequent (5
times or less) cough group (cough [−]), respectively.
PERIPHERAL BLOOD EOSINOPHIL COUNT
Eosinophil counts in the fexofenadine group were
significantly higher during the peak pollen season
compared to before the pollen season (p < 0.001), but
eosinophil counts in the pranlukast group before the
pollen season did not differ significantly from those
during the peak pollen season (Fig. 3).
SYMPTOMS
The severity of nasal and ocular symptoms, particu-
larly nasal congestion, during the peak pollen season
was significantly milder in the pranlukast group than
in the fexofenadine group (p < 0.001), and the degree
of impairment in daily activities during the peak pol-
len season was significantly lower in the pranlukast
group than in the fexofenadine group (p = 0.04) (Fig.
4). The frequency of coughing during the pollen sea-
son did not differ between the fexofenadine group (8
18) and the pranlukast group (716), but among the
patients with coughing, the frequency of coughing
was significantly lower in the pranlukast group com-
pared to the fexofenadine group (p = 0.006) (Fig. 5).
RELATIONSHIP BETWEEN AIRWAY RESPON-
SIVENESS AND SYMPTOMS
We examined whether the severity of nasal and ocu-
lar symptoms and the severity and frequency of
coughing during the peak pollen season differed be-
tween patients with increased (PC20Ach < 20,000 μg
mL) and normal airway responsiveness (PC20Ach 
LTRA Regulates Airway Responsiveness
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Fig. 6 Relationship between airway responsiveness to acetylcholine (Ach) and 
symptom scores during the peak polen season in patients treated with 
fexofenadine. P values were calculated using the Mann-Whitney U test. Closed 
bars: PC20Ach＜ 20,000 mg/ml; open bars: PC20Ach ＞＿ 20,000 mg/ml; eror bars 
show S.D. In the pranlukast group, p values were not calculated due to the smal 
number of subjects. 
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20,000 μgmL). Overall, the mean scores for sneez-
ing and nasal congestion and the frequency and se-
verity of coughing were significantly higher in pa-
tients with increased airway responsiveness. Patients
in each treatment group were similarly classified into
two subgroups based on airway responsiveness. In
both treatment groups, the frequency and severity of
sneezing, nasal congestion, and coughing were sig-
nificantly higher in patients with increased airway re-
sponsiveness. In the pranlukast group, the frequency
and severity of nasal congestion and coughing were
also high, but statistical analysis was not performed
because of the small number of patients (Fig. 6).
There was a strong correlation between airway hy-
perresponsiveness and nasal symptom score, such as
the scores for runny nose, sneezing, nasal conges-
tion, and frequency or severity score of cough (Fig.
7).
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Table 4 Multiple linear regression analysis of airway 
hyperesponsiveness including nasal/ocular symptoms, 
cough, daily activities, and eosinophil counts during the 
peak polen season in al patients (n＝34)
P valueStandard erorCoeficients
0.6229382981.92 1486.18    Runny nose
0.1377613139.27－4827.33    Sneeziong
0.0462811317.44－2775.12    Stufy nose
0.8577073458.65－627.114   Itchy nose
0.8618622349.52－413.431   Itchy eyes
0.6830282385.82－986.674   Watery nose
0.0734142385.94－4475.87    Cough (frequency) 
0.3548443867.30 3651.79    Cough (severity) 
0.7779142983.23－851.327   Daily activity
0.936264   2.456590.198604Eosinophil counts
Fig. 7 Factors influencing airway hyperesponsiveness. The data shows the corelation of airway respon
siveness to acetylcholine (PC20Ach) with the runny nose score, sneezing score, stufy nose score, fre
quency of cough, severity of cough, and peripheral blood eosinophil counts during the peak polen season 
in al patients (n＝34). These corelations were evaluated by using pearson’ scorelation coeficient test.
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MULTIPLE LINEAR REGRESSION ANALYSIS OF
AIRWAY RESPONSIVENESS INCLUDING NA-
SALOCULAR SYMPTOM SCORE
The results of multiple linear regression analysis in-
cluded the nasalocular symptom score, frequency or
severity score of cough, daily activity score, and
eosinophil counts. As shown in Table 4, only the
score of stuffy nose was correlated with airway re-
sponsiveness.
RELATIONSHIP BETWEEN COUGHING AND
AIRWAY RESPONSIVENESS
We also examined the effects of treatment on airway
responsiveness in each group according to the pres-
ence or absence of coughing during the pollen sea-
son. In the fexofenadine group, the AC20Ach level de-
creased significantly during the peak pollen season,
compared with the value before the pollen season, re-
gardless of the presence or absence of coughing (Fig.
8). In particular, airway responsiveness increased in
all patients with coughing, whereas AC20Ach levels
during the peak pollen season decreased significantly
in patients without coughing (p = 0.002). In the pran-
lukast group, the AC20Ach level did not decrease sig-
nificantly during the peak pollen season, compared
with the value before the pollen season, regardless of
the presence or absence of coughing (Fig. 9).
SIDE EFFECTS
There were no clinically important side effects during
the treatment period in either group.
DISCUSSION
The effects of therapeutic agents for allergic rhinitis
on bronchial asthma have been examined widely,
with nasal steroid sprays most frequently evaluated
clinically. Treatment for allergic rhinitis reduces the
risk of asthma and ameliorates airway hyperrespon-
siveness in non-asthmatic patients,15,16 as well as re-
duces episodes and symptoms of asthma in asthmatic
patients.17-19 LTRAs have also been studied in asth-
matic patients,20,21 and may reduce symptoms of al-
lergic rhinitis and bronchial asthma. However, stud-
ies assessing the effects of LTRAs on airway inflam-
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Fig. 8 Seasonal variation of airway responsiveness to acetylcholine (PC20Ach) in sub
jects receiving fexofenadine and mequitazine. Airway responsiveness to acetylcholine 
(PC20Ach) increased significantly during the peak polen season compared with before the 
polen season in subjects with and without cough.
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Fig. 9 Seasonal variation of airway responsiveness to acetylcholine (Ach) in subjects re
ceiving pranlukast and mequitazine. Airway responsiveness to acetylcholine (PC20Ach) 
did not increase significantly during the peak polen season compared with before the pol
len season in subjects with and without cough.
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mation and airway responsiveness in non-asthmatic
patients have not been performed.
We compared the effects of fexofenadine hydro-
chloride plus oral mequitazine and pranlukast hy-
drate plus oral mequitazine on airway responsiveness
and other variables in non-asthmatic patients with ce-
dar pollinosis. In the fexofenadine group, airway re-
sponsiveness increased during the peak pollen sea-
son, compared with that before the pollen season, but
in the pranlukast group airway responsiveness did
not increase, indicating that pranlukast hydrate inhib-
its increased airway responsiveness caused by cedar
Sagara H et al.
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pollinosis. These findings also suggest that cysteinyl
leukotrienes are related to increased airway respon-
siveness in patients with cedar pollinosis.
Recently, it is well known that there is a relation-
ship between allergic rhinitis and lower airway disor-
ders. It is estimated that allergic rhinitis might impact
asthma through several mechanisms, such as the rhi-
nobronchial reflex, an irritant mechanism sustained
by postnasal drip, or oral respiration caused by nasal
obstruction, but some controversy remains.22 Regard-
ing the relationship between airway hyperresponsive-
ness and nasal and ocular symptoms, the scores for
sneezing, nasal congestion, and symptoms were
higher in patients with increased airway responsive-
ness. There was a strong correlation between airway
hyperresponsiveness and symptoms, such as runny
nose, sneezing, stuffy nose, and cough (Fig. 7). Stuffy
nose showed a correlation with airway responsive-
ness in multiple linear regression analysis (p = 0.046)
(Table 4). Stuffy nose scores were lower in the pran-
lukast group, which included fewer patients with in-
creased airway responsiveness. Controlled, double-
blind, multicenter trials in patients with perennial al-
lergic rhinitis have shown that pranlukast hydrate is
more effective than second-generation antihistamines
for nasal congestion,23 suggesting that nasal conges-
tion may be related to increased airway responsive-
ness.
High cedar pollen counts often cause pharyngeal
pruritus and coughing, in addition to nasal symp-
toms.24 Cedar pollen counts were very high in 2005
and about 44% of our patients had coughing during
the pollen season. Therefore, we examined if airway
responsiveness is related to the frequency and sever-
ity of coughing during the cedar pollen season.
Scores for both the frequency and severity of cough-
ing were significantly higher in patients with in-
creased airway responsiveness, compared to those
with normal airway responsiveness, and also there
were strong correlations between airway responsive-
ness and both the frequency and severity of cough-
ing. These results suggest that airway hyperrespon-
siveness is related to coughing in patients with cedar
pollinosis. In contrast, the frequency and severity of
coughing did not differ significantly between the
fexofenadine group and the pranlukast group, sug-
gesting that LTRA treatment was ineffective against
cough. These findings suggest that cysteinyl leukot-
rienes contribute minimally to coughing. However,
among patients with coughing, the frequency of
coughing was significantly lower in the pranlukast
group, and Brozmanova et al. have recently reported
that montelukast inhibits the cough reflex in a guinea
pig model of allergic rhinitis.25 Given these findings,
further studies are needed to define the relationship
between cysteinyl leukotrienes and coughing.
Our results show that cysteinyl leukotrienes influ-
ence airway hyperresponsiveness in non-asthmatic
patients with cedar pollinosis. In particular, airway re-
sponsiveness markedly increased during the peak
pollen season in patients with coughing, suggesting
an association between coughing and airway hyperre-
sponsiveness. In contrast, non-asthmatic patients with
pollinosis have eosinophilic infiltration of the airway
mucosa and elevated interleukin-5 levels, in addition
to airway hyperresponsiveness.26 Airway inflamma-
tion was not examined in the present study, but pran-
lukast hydrate inhibited peripheral blood eosino-
philia, as well as airway hyperresponsiveness, and is
therefore likely to suppress airway inflammation.
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